Despite intense research on autoimmune diseases like lupus, little is still known on how the immune system works to attack the patient’s tissues and organs. However, a recent study titled “Neutrophil trails guide influenza specific CD8+ T cells in the airways” and published early this month in the…
The Lupus Foundation of America has invited Scottsdale, Arizona’s Mayor, Jim Lane, as its guest of honor during the annual Walk to End Lupus Now fundraiser, the largest lupus walk program in the country, which is set to take place at the Scottsdale Center for the Arts on Saturday, September 19,…
NEOVACS, a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases, announced it has been granted initial approvals by regulatory agencies and ethics committees in several countries in the European Union for a Phase IIb clinical study of investigational IFNα-Kinoid for patients…
Pregnant women with lupus (a rheumatic autoimmune condition) have an increased risk of transmitting the condition to their newborns, especially if they have lupus or Sjögren’s syndrome along with antibodies to SSA/Ro and/or SSB/La proteins. According to Dr. Jill P. Buyon, M.D., professor of medicine and director of the Division of Rheumatology at NYU,…
XTL Biopharmaceuticals Ltd., a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet clinical needs, recently announced the results of a Phase 2b study on the efficacy and safety of its investigational drug candidate, hCDR1 (Edratide) for the treatment of systemic lupus…
Results from a study recently published in the journal Arthritis Care and Research showed that the lower extremity strength or weakness of women with systemic lupus erythematosus (SLE) was predictive of later higher or lower functional status but was unrelated to grip strength. Evidence showed that reduced…
While biomedical research and development has come a long way in understanding lupus and how to manage it, experts believe they have barely made a dent in this autoimmune disease’s complexity and elusiveness. Many diseases stem from and degrade specific organs, which leads to tell-tale symptoms. Lupus, however, tends to…
Australian pharmaceutical giant Invion Limited, recently completed its phase II clinical study on INV103 (ala-Cpn10) in patients with systemic lupus erythematosus (SLE). The study was designed to test the biochemical properties of the drug in escalating doses, administered to patients with SLE and other autoimmune disorders, in considerably higher numbers…
Results from a Phase 2a clinical trial  recently presented during the European League Against Rheumatism Annual European Congress of Rheumatology revealed regional differences in the response to sifalimumab treatment in systemic lupus erythematosus (SLE) patients. Sifalimumab (formerly MEDI-545) is an investigational human monoclonal antibody that targets IFN-α, a type of inflammatory cytokine in…
Results from a phase 2 clinical trial recently published in the journal Lupus Science and Medicine revealed that edratide (hCDR1, Teva) is effective and has high tolerability in patients with a diagnosis of systemic lupus erythematosus (SLE). However, the study failed to meet its primary endpoints.